CLEARBRIDGE HEALTH LIMITED

(Incorporated in the Republic of Singapore) (Company Registration No. 201001436C)

ISSUE AND ALLOTMENT OF 995,160 ORDINARY SHARES IN THE CAPITAL OF THE COMPANY PURSUANT TO THE CLEARBRIDGE HEALTH PERFORMANCE SHARE PLAN

Unless otherwise defined, capitalised terms used herein shall bear the same meanings ascribed to them in the Company's announcement dated 28 April 2021 ("Announcement").

Further to the Announcement, the Board wishes to announce that the Company had, on 28 April 2022 allotted and issued 995,160 new ordinary shares (the "Award Shares") in the capital of the Company pursuant to the Awards vested under the Clearbridge Health Performance Share Plan.

Following the allotment and issuance of the Award Shares, the issued and paid-up share capital of the Company has increased from 617,215,180 shares to 618,210,340 shares. The Award Shares rank pari passu in all respects with the existing shares of the Company.

The Award Shares will be listed and quoted on the Catalist Board of the Singapore Exchange Securities Trading Limited on or about 29 April 2022.

BY ORDER OF THE BOARD

Chen Johnson Non-Executive Non-Independent Chairman

28 April 2022

This announcement has been prepared by Clearbridge Health Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.